

American Journal of Clinical Dermatology

Topical Antimicrobial Treatment of Acne Vulgaris

An Evidence-Based Review

Ryan Gamble et al.

Supplemental Digital Content

This Supplemental Digital Content contains the table referred to in the full version of this article, which can be found at <http://adisonline.com/dermatology>

© 2012 Adis Data Information BV. All rights reserved.

Conflicts of interest for studies published since 2004

Group	Self-reported COI	COI according to http://projects.propublica.org/docdollars/
UK National Health Service Clinical Knowledge Summary ^[38]	No COI reported	
American Academy of Dermatology ^[4]	Roche, Medicis, SkinMedia, Galderma, Stiefel, Obaj, Connetics, Collagenex, Allergan, Dow, Healthpoint, Johnson & Johnson, QLT, Berlex, Bradley/Doak, Ranbaxy, Atrix, Dermik, Amgen, Astellas, Bristol Meyers Squibb, GlaxoSmithKline, Genentech, Warner Chilcott, Merck, Anacor, Dow Pharmaceutical Sciences	Dr Shalita: Johnson & Johnson, GlaxoSmithKline; Dr Thiboutot: GlaxoSmithKline, Valeant; Dr Bhushan: Eli Lilly, Pfizer
Global Alliance to Improve Outcomes in Acne ^[74]	Galderma, Kao, Stiefel, Dusa, Johnson & Johnson, Ortho Neutrogena, Intendis, Astellas, La Roche Posay, Expansicone, Pierre Fabre, Biollevis, York Pharma, Schering, Basilea, IMTM, Vichy, Bioderma, Schering-Plough, Ranbaxy, Janssen-Cilag, Allergan, Obagi, SkinMedica, Medicis, Otsuka, Sanofi, Novartis, Roche, Biolab, Pfizer, L'Oreal, Baxbier, Quinoa, Ortho, Dermik, QLT	Dr Thiboutot: GlaxoSmithKline, Valeant; Dr Shalita: Johnson & Johnson, GlaxoSmithKline; Dr Berson: GlaxoSmithKline; Dr Martin: Pfizer
Institute for Clinical Systems Improvement ^[5]	No COI reported	
Kircik ^[44] (n = 65)	Johnson & Johnson, Galderma, Medicis Pharmaceuticals, Stiefel Laboratories	GlaxoSmithKline, Allergan, Pfizer, Johnson & Johnson
Thiboutot et al. ^[43] (n = 2813)	Allergan, Arcutis, Dusa, Galderma, Stiefel, QLT, Medicis, Sanofi, Dusa,	Dr Thiboutot: GlaxoSmithKline, Valeant; Dr Weiss: GlaxoSmithKline, Johnson &

Langner et al. ^[87] (n = 130)	Ortho, Coria, Cutanea, Dow Pharmaceutical Sciences Stiefel International R&D	Johnson, Eli Lilly; Dr Webster: GlaxoSmithKline, Johnson & Johnson Authors were from the UK and Poland and are not listed in the Propublica database
Ozolins et al. ^[48] (n = 649)	Stiefel, Dermik Laboratories (Aventis), Adams Healthcare	Authors were from the UK and are not listed in the Propublica database
Leyden et al. ^[80] (n = 30)	Dr Leyden is a consultant for Galderma Laboratories, L.P. Drs Preston, Osborn, and Gottschalk are employees of Galderma Laboratories, L.P. This study was funded by Galderma Laboratories, L.P.	Drs Leyden, Preston, and Osborn are not listed in the Propublica database; Dr Gottschalk: Eli Lilly
Jackson, et al. ^[83] (n = 54)	Dr Jackson has performed research or consulting, or received honoraria and/or support from the following companies: 3M, Abbott, Amgen, Biogen, Centocor, Ferndale, Galderma, Genentech, Medicis, Novartis, Roche, Stiefel. Dr Fu has performed research or consulting, or received honoraria and/or support from the following companies: Amgen, Abbott, Allergan, Dermik, Galderma, Genentech, Intendis, Medicis, Norvartis, Procter and Gamble, Stiefel. Ms. Almekinder is an employee of Stiefel, a GlaxoSmithKline company	Dr Jackson: GlaxoSmithKline; Dr Fu is not listed in the Propublica database
Gollnick et al. ^[50] (n = 1670)	This study was funded by Galderma R&D, Princeton, NJ, USA. The investigating authors received payments for this research project. B.G., Y.L., and M.G. are employees of Galderma R&D. H.P.M.G. has served as a speaker for Galderma Laboratories	Dr Draelos: Allergan, Pfizer; Dr Cornelison: Johnson & Johnson, Drs Gollnick, Rosoph and Kaszuba are not listed in the Propublica database
Bowman, et al. ^[84] (n = 132)	Dr Gold has received honoraria for speaking on	Dr Bowman: GlaxoSmithKline, Pfizer; Dr Gold: Pfizer; Drs Nasir

Fleischer, et al. ^[60] (n = 301)	<p>behalf of Dermik Laboratories. Dr Bowman and Dr Nasir have nothing to disclose. Mr Vamvakias is an employee of Dermik Laboratories. This study was supported by Dermik Laboratories QLT USA, Inc., Fort Collins, CO, USA sponsored this study. Dr Fleischer is a member on an advisory board for Allergan, Amgen, Astellas, Galderma, GlaxoSmithKline, Ortho Dermatologics, Stiefel. Dr Fleischer is also a consultant for Allergan, Astellas, Asubio, Combe, Galderma, Gerson Lehrman, Intendis, Kikaku America International, Merz, Novartis, Serentis, Taisho, has received funding for studies from 3M, Abbott, Allergan, Amgen, Astellas, Asubio, Biogen, BioCryst, Dow, Centocor, Coria, Galderma, GlaxoSmithKline, Genentech, Intendis, Medicis, Novartis, Ortho Dermatologics, Pfizer, Serentis, Stiefel, Taisho, and has participated in a speaker's bureau for Amgen, Astellas, Galderma, Intendis, Medicis, Novartis, Stiefel. Dr Shalita was an investigator for topical dapsone. He is a consultant for Allergan, Galderma, Medicis, Stiefel and has a minor equity interest in Allergan, Medicis, Johnson & Johnson. Dr Eichenfield is a consultant for Allergan, Inc. Dr Abramovits is an advisor</p>	<p>and Vamvakias are not listed in the Propublica database</p> <p>Dr Fleischer: Johnson & Johnson; Dr Abramowits: Pfizer, GlaxoSmithKline, Johnson & Johnson; Dr Eichenfield: GlaxoSmithKline, Johnson & Johnson; Dr Shalita: GlaxoSmithKline, Johnson & Johnson</p>
---------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

for Abbott, Allergan, Amgen, Barrier Therapeutics, Collagenex, Graceway, Galderma, Medicis, QLT USA, Quinnova, Sanofi, Stiefel, a consultant for Allergan, Amgen, Astellas, Graceway, Galderma, Medicis, QLT USA, Quinnova, Sanofi, Stiefel, Warner Chilcott, has received grant funding from Abbott, Amgen, Astellas, Bavarian Nordic, Graceway, Collagenex, Cotech, Galderma, Medicis, NanoBio, Photocure, QLT, Sanofi, Sinclair, Shionogi, Stiefel, and has participated in a speaker's bureau for Abbott, Allergan, Amgen, Galderma, Genentech, Medicis, Promius, Sanofi, Stiefel, UCBI. Dr Lucky is a consultant for Altana, Johnson & Johnson, Novum, Stiefel. Dr Garrett was an employee of QLT USA, Inc., when this study was conducted, has received consulting fees from QLT USA, Inc., and holds stock options in QLT Inc

Pazoki-Toroudi et al. ^[64] (n = 130)	No COI reported	Authors were from Iran and are not listed in the Propublica database
Pazoki-Toroudi et al. ^[65] (n = 147)	No COI reported	Authors were from Iran and are not listed in the Propublica database
Langner et al. ^[61] (n = 148)	This study was supported by Stiefel International R&D	Authors were from Europe and are not listed in the Propublica database

COI = conflicts of interest.

References

- [1] Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. *J Am Acad Dermatol* 2009; 60 (5 Suppl.): S1-50
- [2] Tan HH. Topical antibacterial treatments for acne vulgaris: comparative review and guide to selection. *Am J Clin Dermatol* 2004; 5 (2): 79-84
- [3] Brown SK, Shalita AR. Acne vulgaris. *Lancet* 1998; 351 (9119): 1871-6
- [4] Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. *J Am Acad Dermatol*. 2007; 56 (4): 651-63
- [5] Institute for Clinical Systems Improvement. Neely C, Davis M, Lee J, et al. ICSI acne guidelines, 2006 [online]. Available from URL: http://www.icsi.org/acne/acne_management_3.html [Accessed 2011 Apr 17]
- [6] Patel M, Bowe WP, Heughebaert C, et al. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. *J Drugs Dermatol* 2010; 9 (6): 655-64
- [7] Purdy S, de Berker D. Acne vulgaris. *Clin Evid (Online)*. Epub 2011 Apr 12
- [8] What role for topical antibacterials in acne? *Drug Ther Bull* 2010; 48 (12): 141-4
- [9] Dutil M. Benzoyl peroxide: enhancing antibiotic efficacy in acne management. *Skin Therapy Lett* 2010; 15 (10): 5-7
- [10] Krakowski AC, Stendardo S, Eichenfield LF. Practical considerations in acne treatment and the clinical impact of topical combination therapy. *Pediatr Dermatol* 2008; 25 Suppl. 1: 1-14
- [11] Fakhouri T, Yentzer BA, Feldman SR. Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability. *J Drugs Dermatol* 2009; 8 (7): 657-61
- [12] Del Rosso JQ, Kim GK. Topical antibiotics: therapeutic value or ecologic mischief? *Dermatol Ther* 2009; 22 (5): 398-406
- [13] Del Rosso JQ, Leyden JJ, Thiboutot D, et al. Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists. *Cutis* 2008; 82 (2 Suppl. 2): 5-12
- [14] Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. *Cutis* 2007; 79 (6 Suppl.): 9-25
- [15] Tan AW, Tan HH. Acne vulgaris: a review of antibiotic therapy. *Expert Opin Pharmacother* 2005; 6 (3): 409-18
- [16] Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. *Br J Dermatol* 2005; 153 (2): 395-403
- [17] Williams HC, Dellavalle RP, Garner S. Acne vulgaris. *Lancet*. Epub 2011 Aug 29
- [18] Chivot M. Retinoid therapy for acne. A comparative review. *Am J Clin Dermatol* 2005; 6 (1): 13-9
- [19] Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. *J Drugs Dermatol* 2008; 7 (6 Suppl.): s3-10
- [20] Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. *J Am Acad Dermatol* 2003; 49 (1 Suppl.): S1-37
- [21] Gollnick H, Schramm M. Topical therapy in acne. *J Eur Acad Dermatol Venereol* 1998; 11 Suppl. 1: S8-12; discussion S28-9
- [22] Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. *J Am Acad Dermatol* 2003; 49 (3 Suppl.): S200-10

- [23] Mills OH, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. *Acta Derm Venereol* 1978; 58 (6): 555-7
- [24] Martin B, Meunier C, Montels D, et al. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. *Br J Dermatol* 1998; 139 Suppl. 52: 8-11
- [25] Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. *J Am Acad Dermatol* 1997; 37 (4): 590-5
- [26] Bojar RA, Eady EA, Jones CE, et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. *Br J Dermatol* 1994; 130 (3): 329-36
- [27] Mills OH, Kligman AM, Pochi P, et al. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. *Int J Dermatol* 1986; 25 (10): 664-7
- [28] Lyons RE. Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. *Int J Dermatol*. 1978; 17 (3): 246-51
- [29] Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. *Clin Exp Dermatol* 1992; 17 (3): 165-8
- [30] Bucknall JH, Murdoch PN. Comparison of tretinoin solution and benzoyl peroxide lotion in the treatment of acne vulgaris. *Curr Med Res Opin* 1977; 5 (3): 266-8
- [31] Handojo I. Retinoic acid cream (Ainol cream) and benzoyl-peroxide in the treatment of acne vulgaris. *Southeast Asian J Trop Med Public Health* 1979; 10 (4): 548-51
- [32] Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. *Pediatrics* 2006; 118 (3): 1188-99
- [33] Weinberg JM. The utility of benzoyl peroxide in hydrophase base (Brevoxyl) in the treatment of acne vulgaris. *J Drugs Dermatol* 2006; 5 (4): 344-9
- [34] Sawleshwarkar SN, Salgaonkar V, Oberai CM. Multicenter study to evaluate efficacy and irritation potential of benzoyl peroxide 4% cream in hydrophase base (Brevoxyl) in acne vulgaris. *Indian J Dermatol Venereol Leprol* 2003; 69 (1): 19-22
- [35] Gold LS. Fixed-combination products in the management of acne vulgaris. *Cutis* 2010; 85 (3): 160-7
- [36] Gold MH. A multicenter efficacy and tolerability evaluation of benzoyl peroxide in a 10% urea vehicle for the treatment of acne vulgaris. *J Drugs Dermatol* 2006; 5 (5): 442-5
- [37] Jelvehgari M, Siahi-Shadbad MR, Azarmi S, et al. The microsphere delivery system of benzoyl peroxide: preparation, characterization and release studies. *Int J Pharm* 2006; 308 (1-2): 124-32
- [38] UK National Health Service Clinical Knowledge Summary. Acne vulgaris, 2009 [online]. Available from URL: <http://www.cks.nhs.uk/search?&page=1&q=acne%20vulgaris&site=0> [Accessed 2011 Apr 13]
- [39] Kinney MA, Yentzer BA, Fleischer AB, et al. Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance? *J Drugs Dermatol* 2010; 9 (5): 519-24
- [40] Chalker DK, Shalita A, Smith JG, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. *J Am Acad Dermatol* 1983; 9 (6): 933-6
- [41] Tschen E. Potential role for a new combination topical therapy in treating mild to moderate acne vulgaris. *Cutis* 2001; 67 (2 Suppl.): 25-7
- [42] Leyden J. Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. *Introduction Cutis* 2001; 67 (2 Suppl.): 5-7

- [43] Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. *J Am Acad Dermatol* 2008; 59 (5): 792-800
- [44] Kircik L, Green L, Thiboutot D, et al. Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: final data from a multicenter, investigator-blind, randomized study. *J Drugs Dermatol* 2009; 8 (9): 812-8
- [45] Seidler E, Kimball AB. Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2.5% benzoyl peroxide and clindamycin topical treatments in acne [abstract]. *J Am Acad Dermatol* 2011; 64 (2): AB6
- [46] Bucks D, Angel A, Del Rosso J, et al. Can delivery be enhanced and skin irritation minimized using a lower concentration of benzoyl peroxide in a fixed combination product [abstract]? *J Am Acad Dermatol* 2009; 60 (3): AB16
- [47] Ozolins M, Eady EA, Avery A, et al. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. *Health Technol Assess* 2005; 9 (1): iii-212
- [48] Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. *Lancet* 2004; 364 (9452): 2188-95
- [49] Wolf JE, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. *J Am Acad Dermatol* 2003; 49 (3 Suppl.): S211-7
- [50] Gollnick HP, Draelos Z, Glenn MJ, et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. *Br J Dermatol* 2009; 161 (5): 1180-9
- [51] Nilfroushzadeh MA, Siadat AH, Baradaran EH, et al. Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. *Indian J Dermatol Venereol Leprol* 2009; 75 (3): 279-82
- [52] Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. *Int J Dermatol* 1983; 22 (1): 41-3
- [53] Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. *J Am Acad Dermatol* 2006; 54 (1): 73-81
- [54] Leyden J, Wortzman M, Baldwin EK. Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel. *J Drugs Dermatol* 2009; 8 (4): 383-8
- [55] Draelos Z, Tanghetti E. Optimizing the use of tazarotene for the treatment of facial acne vulgaris: a multicenter, double-blinded, randomized parallel-group trial. *Cutis* 2002; 69 (2 Suppl.): 20-29
- [56] Tanghetti E, Dhawan S, Torok H, et al. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris. *Dermatol Online J* 2007; 13 (3): 1
- [57] Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. *J Am Acad Dermatol* 2003; 49 (3 Suppl.): S227-32
- [58] Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. *J Am Acad Dermatol*. 2007; 56 (3): 439.e1-10
- [59] Piette WW, Taylor S, Pariser D, et al. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. *Arch Dermatol* 2008; 144 (12): 1564-70

- [60] Fleischer AB, Shalita A, Eichenfield LF, et al. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. *J Drugs Dermatol* 2010; 9 (1): 33-40
- [61] Langner A, Sheehan-Dare R, Layton A. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. *J Eur Acad Dermatol Venereol* 2007; 21 (3): 311-9
- [62] Draelos ZD. The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses. *J Drugs Dermatol* 2010; 9 (3): 234-6
- [63] Seidler EM, Kimball AB. Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. *J Am Acad Dermatol* 2010; 63 (1): 52-62
- [64] Pazoki-Toroudi H, Nilforoushzadeh MA, Ajami M, et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. *Cutan Ocul Toxicol* 2011 Dec; 30 (4): 286-91
- [65] Pazoki-Toroudi H, Nassiri-Kashani M, Tabatabaie H, et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. *J Dermatolog Treat* 2010; 21 (3): 212-6
- [66] Graupe K, Cunliffe WJ, Gollnick HP, et al. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. *Cutis* 1996; 57 (1 Suppl.): 20-35
- [67] Thiboutot D. Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. *J Drugs Dermatol* 2008; 7 (1): 13-6
- [68] Burkhart CG, Burkhart CN. Treatment of acne vulgaris without antibiotics: tertiary amine-benzoyl peroxide combination vs. benzoyl peroxide alone (Proactiv Solution). *Int J Dermatol* 2007; 46 (1): 89-93
- [69] Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. *Am J Clin Dermatol* 2003; 4 (12): 813-31
- [70] Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. *Dermatology* 2003; 206 (1): 54-6
- [71] Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. *Med J Aust* 1998; 169 (5): 259-61
- [72] Coates P, Vyakarnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. *Br J Dermatol* 2002; 146 (5): 840-8
- [73] Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. *Br J Dermatol* 2003; 148 (3): 467-78
- [74] Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. *J Am Acad Dermatol* 2009; 60 (5 Suppl.): S1-50
- [75] Nast A, Bayerl C, Borelli C, et al. S2k-guideline for therapy of acne [in German]. *J Dtsch Dermatol Ges* 2010; 8 Suppl. 2: s1-59
- [76] Patel M, Bowe WP, Heughebaert C, et al. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. *J Drugs Dermatol* 2010; 9 (6): 655-64
- [77] Handojo I. The combined use of topical benzoyl peroxide and tretinoin in the treatment of acne vulgaris. *Int J Dermatol* 1979; 18 (6): 489-96
- [78] Shalita AR, Rafal ES, Anderson DN, et al. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. *Cutis* 2003; 72 (2): 167-72

- [79] Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. *J Am Acad Dermatol* 2007; 57 (5): 791-9
- [80] Leyden JJ, Preston N, Osborn C, et al. In-vivo effectiveness of adapalene 0.1%/benzoyl peroxide 2.5% gel on antibiotic-sensitive and resistant *Propionibacterium acnes*. *J Clin Aesthet Dermatol* 2011; 4 (5): 22-6
- [81] Nast A, Dreno B, Bettoli V, et al. European evidence based (S3) guideline for treatment of acne (ICD L70.0). EU Acne Guidelines Group; draft version 13/5/2011 [online]. Available from URL: http://www.acne-guideline.com/home_eu/External_open_review/ [Accessed 2011 May 28]
- [82] Acne Working Group. Management of mild and moderate acne vulgaris. *GP Review* 2008 Jan 1-11
- [83] Jackson JM, Fu JJ, Almekinder JL. A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. *J Drugs Dermatol* 2010; 9 (2): 131-6
- [84] Bowman S, Gold M, Nasir A, et al. Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. *J Drugs Dermatol* 2005; 4 (5): 611-8
- [85] Alexis AF. Clinical considerations on the use of concomitant therapy in the treatment of acne. *J Dermatolog Treat* 2008; 19 (4): 199-209
- [86] Gupta AK, Lynde CW, Kunyetz RA, et al. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. *J Cutan Med Surg* 2003; 7 (1): 31-7
- [87] Langner A, Chu A, Goulden V, et al. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. *Br J Dermatol* 2008; 158 (1): 122-9
- [88] Burkhart CG, Scheinfeld NS. Benzoyl peroxide skin washes: basis, logic, effectiveness, and tolerance. *Skinmed* 2005; 4 (6): 370
- [89] Kraus AL, Munro IC, Orr JC, et al. Benzoyl peroxide: an integrated human safety assessment for carcinogenicity. *Regul Toxicol Pharmacol* 1995; 21 (1): 87-107
- [90] Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. *J Am Acad Dermatol* 1988; 19 (3): 431-42
- [91] Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. *Arch Dermatol* 1986; 122 (5): 583-4
- [92] Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. *Cutis* 2010; 86 (2): 103-8
- [93] Bikowski J. A review of the safety and efficacy of benzoyl peroxide (5.3%) emollient foam in the management of truncal acne vulgaris. *J Clin Aesthet Dermatol* 2010; 3 (11): 26-9
- [94] Nguyen D, Ornstein C, Weber T. Dollars for docs: how industry dollars reach your doctors [online]. Available from URL: <http://projects.propublica.org/docdollars/> [Accessed 2011 Sep 15]